NAMENDA (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. 2. DOSAGE AND ADMINISTRATION. The ...

NAMENDA XR® is indicated for the treatment of moderate to severe dementia of the. Alzheimer's type. 2. DOSAGE AND ADMINISTRATION. 2.1 Recommended Dosing. The ...

View names and safety data sheets for our products. The product information provided below is intended for residents of the US only.

15 нояб. 2022 г. · A protracted legal fight over an alleged "pay-for-delay" deal on AbbVie's Alzheimer's disease drug Namenda may be nearing its end.

6 нояб. 2024 г. · NAMENDA (memantine hydrochloride - tablet;oral). Manufacturer: ABBVIE Approval date: October 16, 2003. Strength(s): 5MG, 10MG ...

28 окт. 2019 г. · Forest will pay a total of $750 million to the direct purchaser class, subject to finalization of the settlement agreement and court approval.

24 мар. 2023 г. · AbbVie Inc. and Merz Holding Gmbh & Co. affiliates received final approval for a $54.4 million settlement of a lawsuit that claimed the ...

14 нояб. 2022 г. · AbbVie Inc has agreed to pay $54.4 million to settle a proposed class action brought by health plans that claim they overpaid for the Alzheimer's drug Namenda.

6 нояб. 2024 г. · NAMENDA XR (memantine hydrochloride - capsule, extended release;oral). Manufacturer: ABBVIE Approval date: June 21, 2010. Strength(s): 14MG ...

14 июн. 2021 г. · AbbVie subsidiary Forest Laboratories has been battling in the courts for seven years over its efforts to extend patents for its Alzheimer's drug Namenda.